BridgeBio Oncology Therapeutics Inc. (BBOT) ownership: Top institutional holder: Cormorant Asset Management, LP ($160.01M). Insider activity: Net Seller (3 buys, 17 sells). SEC EDGAR first-party data.
| Holder | Shares | Market Value | Reported |
|---|---|---|---|
| Cormorant Asset Management, LP | 17878594.00 | $160.01M | 2026-03-31 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 4885446.00 | $43.72M | 2026-03-31 |
| Catalio Capital Management, LP | 410700.00 | $31.41M | 2025-12-31 |
| Omega Fund Management, LLC | 3289661.00 | $29.44M | 2026-03-31 |
| EcoR1 Capital, LLC | 2823126.00 | $25.27M | 2026-03-31 |
| Alphabet Inc. | 2823126.00 | $25.27M | 2026-03-31 |
| WELLINGTON MANAGEMENT GROUP LLP | 2818348.00 | $25.22M | 2026-03-31 |
| ENAVATE SCIENCES GP, LLC | 2626946.00 | $23.51M | 2026-03-31 |
| Insider | Transaction | Value | Date |
|---|---|---|---|
| Sell | null | 2026-06-16 | |
| Sell | null | 2026-06-16 | |
| Sell | null | 2026-06-16 | |
| Sell | null | 2026-06-16 | |
| Sell | null | 2026-06-16 | |
| Sell | null | 2026-06-16 | |
| Sell | null | 2026-06-16 | |
| Sell | null | 2026-05-10 |
Back to BBOT overview · BBOT earnings · All congressional trades
Institutional data from SEC Form 13F. Insider data from SEC Form 4. Congressional data from STOCK Act disclosures. Not personalized investment advice.